Dual STAT-3 and IL-6R Inhibition with Stattic and Tocilizumab Decreases Migration, Invasion and Proliferation of Prostate Cancer Cells by Targeting the IL-6/IL-6R/STAT-3 Axis

Researchers investigated the effect of Stattic and Tocilizumab on proliferative, clonogenic, migratory, and invasive ability of human metastatic prostate cancer, as assessed by colony formation, wound healing, and migration assay.